Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cytokine ; 15(2): 87-95, 2001 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-11500084

RESUMO

The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence against Aspergillus. M-CSF (100-600 microg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P<0.001). PAMs harvested from rabbits treated with M-CSF had a significantly greater percent phagocytosis of Aspergillus fumigatus conidia than did PAMs from controls (P=0.04). These data indicate that prophylactic administration of M-CSF augments pulmonary host defence against A. fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia.


Assuntos
Antifúngicos/farmacologia , Aspergilose/tratamento farmacológico , Pneumopatias Fúngicas/tratamento farmacológico , Fator Estimulador de Colônias de Macrófagos/farmacologia , Animais , Aspergilose/imunologia , Aspergilose/patologia , Aspergillus fumigatus/efeitos dos fármacos , Feminino , Humanos , Pneumopatias Fúngicas/imunologia , Pneumopatias Fúngicas/patologia , Macrófagos/imunologia , Fagocitose/efeitos dos fármacos , Fagocitose/imunologia , Pneumonia/tratamento farmacológico , Pneumonia/microbiologia , Pneumonia/patologia , Alvéolos Pulmonares/patologia , Embolia Pulmonar/tratamento farmacológico , Embolia Pulmonar/patologia , Coelhos , Proteínas Recombinantes , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA